{"id":"https://openalex.org/W2783003641","doi":"https://doi.org/10.1208/s12248-017-0182-5","title":"Common Deficiencies of in vitro Binding Bioequivalence (BE) Studies Submitted in Abbreviated New Drug Applications (ANDAs)","display_name":"Common Deficiencies of in vitro Binding Bioequivalence (BE) Studies Submitted in Abbreviated New Drug Applications (ANDAs)","alternate_titles":[],"publication_year":2018,"publication_date":"2018-01-11","ids":{"openalex":"https://openalex.org/W2783003641","doi":"https://doi.org/10.1208/s12248-017-0182-5","mag":"2783003641","pmid":"https://pubmed.ncbi.nlm.nih.gov/29327295"},"language":"en","primary_location":{"id":"doi:10.1208/s12248-017-0182-5","doi":"https://doi.org/10.1208/s12248-017-0182-5","is_oa":false,"landing_page_url":"https://doi.org/10.1208/s12248-017-0182-5","pdf_url":null,"source":{"id":"https://openalex.org/S74983066","display_name":"The AAPS Journal","issn_l":"1550-7416","issn":["1550-7416"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The AAPS Journal","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2783003641"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101597457","display_name":"Dongmei Lu","orcid":"https://orcid.org/0000-0001-5139-1847","observed_orcids":["https://orcid.org/0000-0001-5139-1847"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Dongmei Lu","raw_affiliation_strings":["Division of Bioequivalence II, Office of Bioequivalence, Office of Generic Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. dongmei.lu@fda.hhs.gov","Division of Bioequivalence II, Office of Bioequivalence, Office of Generic Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Bioequivalence II, Office of Bioequivalence, Office of Generic Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. dongmei.lu@fda.hhs.gov","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]},{"raw_affiliation_string":"Division of Bioequivalence II, Office of Bioequivalence, Office of Generic Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039165759","display_name":"Diana Vivian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diana Vivian","raw_affiliation_strings":["Division of Bioequivalence II, Office of Bioequivalence, Office of Generic Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Bioequivalence II, Office of Bioequivalence, Office of Generic Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Ping Ren","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ping Ren","raw_affiliation_strings":["Division of Therapeutic Performance, Office of Research and Standard, Office of Generic Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Therapeutic Performance, Office of Research and Standard, Office of Generic Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002343596","display_name":"Yongsheng Yang","orcid":"https://orcid.org/0000-0002-7546-1210","observed_orcids":["https://orcid.org/0000-0002-7546-1210"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yongsheng Yang","raw_affiliation_strings":["Division of Bioequivalence II, Office of Bioequivalence, Office of Generic Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Bioequivalence II, Office of Bioequivalence, Office of Generic Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062305293","display_name":"Zhang Hongling","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hongling Zhang","raw_affiliation_strings":["Division of Bioequivalence II, Office of Bioequivalence, Office of Generic Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Bioequivalence II, Office of Bioequivalence, Office of Generic Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014846471","display_name":"Xiaojian Jiang","orcid":"https://orcid.org/0009-0003-8592-4690","observed_orcids":["https://orcid.org/0009-0003-8592-4690"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaojian Jiang","raw_affiliation_strings":["Division of Bioequivalence II, Office of Bioequivalence, Office of Generic Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Bioequivalence II, Office of Bioequivalence, Office of Generic Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5009381526","display_name":"Ethan M. Stier","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ethan Stier","raw_affiliation_strings":["Division of Bioequivalence II, Office of Bioequivalence, Office of Generic Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Bioequivalence II, Office of Bioequivalence, Office of Generic Drugs, Center of Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5101597457"],"corresponding_institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"],"apc_list":{"value":5090,"currency":"USD","value_usd":5090},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.00375783,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":93},"biblio":{"volume":"20","issue":"2","first_page":"26","last_page":"26"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.28130000829696655,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.28130000829696655,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.1703999936580658,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11460","display_name":"Analytical Methods in Pharmaceuticals","score":0.15139999985694885,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/abbreviated-new-drug-application","display_name":"abbreviated new drug application","score":0.972000002861023},{"id":"https://openalex.org/keywords/method-validation","display_name":"method validation","score":0.6940000057220459},{"id":"https://openalex.org/keywords/study-design","display_name":"research design","score":0.8479999899864197},{"id":"https://openalex.org/keywords/data-submission","display_name":"data submission","score":0.6499999761581421},{"id":"https://openalex.org/keywords/regulatory-review","display_name":"regulatory review","score":0.4779999852180481},{"id":"https://openalex.org/keywords/generic-drug-approval","display_name":"generic drug approval","score":0.5659999847412109}],"concepts":[{"id":"https://openalex.org/C42404028","wikidata":"https://www.wikidata.org/wiki/Q864940","display_name":"Bioequivalence","level":3,"score":0.8416563272476196},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5884397625923157},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.47939610481262207},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4047061800956726},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.15603893995285034}],"mesh":[{"descriptor_ui":"D000071220","descriptor_name":"Pharmaceutical Research","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":true},{"descriptor_ui":"D010710","descriptor_name":"Phosphates","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D012107","descriptor_name":"Research Design","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":true},{"descriptor_ui":"D013810","descriptor_name":"Therapeutic Equivalency","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014486","descriptor_name":"United States Food and Drug Administration","qualifier_ui":"Q000331","qualifier_name":"legislation & jurisprudence","is_major_topic":false},{"descriptor_ui":"D014486","descriptor_name":"United States Food and Drug Administration","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":false},{"descriptor_ui":"D016568","descriptor_name":"Drugs, Generic","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016568","descriptor_name":"Drugs, Generic","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D017277","descriptor_name":"Drug Approval","qualifier_ui":"Q000331","qualifier_name":"legislation & jurisprudence","is_major_topic":true},{"descriptor_ui":"D041981","descriptor_name":"Gastrointestinal Tract","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D054928","descriptor_name":"Validation Studies as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1208/s12248-017-0182-5","doi":"https://doi.org/10.1208/s12248-017-0182-5","is_oa":false,"landing_page_url":"https://doi.org/10.1208/s12248-017-0182-5","pdf_url":null,"source":{"id":"https://openalex.org/S74983066","display_name":"The AAPS Journal","issn_l":"1550-7416","issn":["1550-7416"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The AAPS Journal","raw_type":"journal-article"},{"id":"pmid:29327295","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29327295","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The AAPS journal","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8371999859809875}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":5,"referenced_works":["https://openalex.org/W1571805432","https://openalex.org/W1966510289","https://openalex.org/W2002018909","https://openalex.org/W2083290187","https://openalex.org/W2090790944"],"related_works":["https://openalex.org/W2015986906","https://openalex.org/W2080818322","https://openalex.org/W2802908513","https://openalex.org/W2746145072","https://openalex.org/W4391223617","https://openalex.org/W1982801384","https://openalex.org/W4298587263","https://openalex.org/W2368959044","https://openalex.org/W3003750175","https://openalex.org/W2488375702"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2783003641","counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2018-01-26T00:00:00"}
